EquityFlowCompanies › EVerZom

EVerZom

Biotech · Strasbourg, FR

Terapie a base di esosomi da cellule staminali mesenchimali per la medicina rigenerativa.

Funding history

DateRoundAmount
Oct 2025Funding round
EVerZom raised €10 million to start the first clinical trial of EVerGel against Crohn's perianal fistulas in 2026.
$11.6M

Investors

Aloe Private EquityCapital CellCapital Grand EstEIC FundParis Business AngelsSorbonne Venture by Audacia

Similar companies in Biotech

Explore funding flow on EquityFlow →